Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 11/20 | 0.69 |
| ▸ | GSK3A | P49840 | 11/20 | 0.69 |
| ▸ | GSK3B | P49841 | 10/20 | 0.69 |
| ▸ | CDK2 | P24941 | 10/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 9/20 | 0.69 |
| ▸ | KDR | P35968 | 9/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 9/20 | 0.69 |
| ▸ | MAPK9 | P45984 | 9/20 | 0.69 |
| ▸ | CSNK1D | P48730 | 9/20 | 0.69 |
| ▸ | CDK1 | P06493 | 9/20 | 0.69 |
| ▸ | LIMK1 | P53667 | 8/20 | 0.69 |
| ▸ | DAPK3 | O43293 | 8/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.69 |
| ▸ | PLK4 | O00444 | 8/20 | 0.69 |
| ▸ | RPS6KA3 | P51812 | 7/20 | 0.69 |
| ▸ | PRKACA | P17612 | 7/20 | 0.69 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.69 |
| ▸ | SGK2 | Q9HBY8 | 7/20 | 0.69 |
| ▸ | PLK3 | Q9H4B4 | 7/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7929872 | 0.88 | GSK3A (0.69) | PIM1GSK3AGSK3BCDK2DYRK1A | |
| SCHEMBL7055360 | 0.87 | PIM1 (0.76) | PIM1GSK3AGSK3BCDK2DYRK1A | |
| SCHEMBL7056280 | 0.84 | MAP3K8 (0.76) | PIM1GSK3AGSK3BCDK2DYRK1A | |
| SCHEMBL7053404 | 0.83 | PIM1 (0.69) | PIM1GSK3AGSK3BCDK2DYRK1A | |
| SCHEMBL5555786 | 0.83 | PIM1 (0.78) | PIM1GSK3AGSK3BCDK2DYRK1A | |
| Formamide SCHEMBL7052564 | 0.82 | PIM1 (0.70) | PIM1GSK3AGSK3BCDK2DYRK1A | |
| SCHEMBL7050653 | 0.82 | GSK3A (1.00) | PIM1GSK3AGSK3BCDK2DYRK1A | |
| SCHEMBL7055380 | 0.82 | PIM1 (1.00) | PIM1GSK3AGSK3BCDK2DYRK1A | |
| SCHEMBL7056743 | 0.81 | GSK3A (1.00) | PIM1GSK3AGSK3BCDK2DYRK1A | |
| SCHEMBL19769174 | 0.81 | PIM1 (0.74) | PIM1GSK3AGSK3BCDK2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | claimed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | claimed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | claimed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | claimed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | claimed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | claimed |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6579882-B2 | Thieno(2,3-d)pyrimidine derivatives | ABBOTT LABORATORIES | 2003-06-17 | — | — | US | disclosed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | disclosed |
| US-6232320-B1 | THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES | ABBOTT LABORATORIES | 2001-05-15 | — | — | US | disclosed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | PIM1 2261/4885GSK3A 3245/4885GSK3B 3044/4885 |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | PIM1 2261/4885GSK3A 3245/4885GSK3B 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.